Clinically reviewed by Dr. Sarah Boss, MD
Contact the prescribing team promptly when planning pregnancy or if pregnancy occurs; valproate and topiramate need urgent medicine-specific advice. Do not independently change psychiatric treatment. Suspected postpartum psychosis or immediate danger to parent or baby requires emergency assessment. Topiramate actions differ by indication, as explained below.
Planning a pregnancy while taking mental-health medication involves two linked priorities: supporting the parent’s health and reducing avoidable risks to the baby. The decision is not simply medicine versus no medicine. Untreated illness, an abrupt treatment change and loss of follow-up can also cause harm. A coordinated review should consider the exact prescription, previous illness, reproductive plans and the support available before and after birth.
Start the conversation before conception when possible
Tell the prescriber about pregnancy plans early, even when the timing is uncertain. A review may involve a psychiatrist, primary-care clinician, maternity team, pharmacist and other specialists. It is easier to consider alternatives and monitoring when there is time to agree a plan rather than making hurried decisions after a positive pregnancy test.
NICE recommends discussing contraception, pregnancy plans, relapse risk and the possible effects of both illness and treatment. Previous response matters: a medicine that has maintained stability after severe episodes cannot be assessed solely through a general list of pregnancy warnings. The review should explain the benefits, risks and uncertainties relevant to the individual. [1]
Bring the complete medicine history
List prescriptions, non-prescription products, supplements and medicines used only occasionally. Include the active ingredient, formulation, actual pattern of use and why each was started. Medicines for epilepsy, migraine, pain or addiction may affect the same discussion, even when they were prescribed by a different service and are not considered psychiatric medication.
Bring a brief history of what happened during previous changes. An earlier relapse, withdrawal difficulty or severe adverse effect can alter the balance of options. Describe the support that helped and any barriers to obtaining treatment. The goal is one coherent plan rather than separate recommendations that the patient must reconcile alone.
Understanding risk without an all-or-nothing label
A medicine’s risk can depend on timing, dose, formulation, other exposures and the condition being treated. Evidence may be stronger for some products than for others. A statement that a medicine can be used if needed does not mean there is no risk, while a warning does not establish that harm has occurred after an exposure.
Ask the clinician to distinguish what is known, what remains uncertain and what monitoring can address. Discuss the risks of recurrence as well as potential medicine effects. A dose too low to treat the illness may still expose the pregnancy without delivering the intended benefit, so independent dose reduction is not a reliable safety strategy. [1]
If pregnancy occurs unexpectedly
Contact the prescribing and maternity teams promptly. Give the medicine name, actual exposure and the best estimate of pregnancy timing. Do not assume that stopping immediately removes an earlier risk or that continuing until the next routine appointment is always appropriate. The correct action depends on the medicine and indication.
Some treatments require urgent specialist review. Valproate and topiramate are particularly important examples. Avoid changing psychiatric or antiseizure treatment independently while trying to interpret conflicting information. Tell the team if medicines have already been stopped, doses missed or symptoms changed; accurate information is more useful than a perfect account of the intended prescription.
Valproate requires specific reproductive safeguards
Valproate carries substantial reproductive risks. UK requirements include a Pregnancy Prevention Program for patients who can become pregnant, with additional restrictions around initiation. These are medicine-specific safeguards, not a general rule for every mood stabilizer. Current local regulatory requirements should be reviewed with the specialist. [2]
Contact the specialist urgently if pregnancy occurs or is being planned. The MHRA advises that no one should stop valproate without specialist advice because the underlying condition must remain controlled. That instruction is not a reason to postpone review; it is a reason to obtain a coordinated alternative plan promptly rather than acting alone.
Reproductive advice also matters for men
Valproate guidance includes precautions for male patients and their partners. The MHRA describes a possible association between paternal exposure around conception and neurodevelopmental outcomes, while acknowledging limitations in the data and uncertainty about causation. This should be discussed accurately, without presenting an association as proof that an individual child will be affected. [2]
Ask the specialist about contraception, fertility concerns and the timing of attempts to conceive. Do not stop a successful treatment independently in response to a headline. Reproductive planning should include both partners’ needs and should distinguish jurisdiction-specific safety measures from general statements about all psychiatric medicines.
Topiramate: the indication changes the immediate advice
Topiramate has important pregnancy restrictions. UK MHRA advice says that someone who suspects pregnancy while taking it for migraine prevention should stop it and contact their doctor. Someone taking it for epilepsy should not stop independently, because seizures may worsen, and should obtain an urgent appointment with the prescribing team. [3]
For another indication, obtain urgent individualized advice rather than assuming the migraine or epilepsy instruction applies. Topiramate can also interact with some hormonal contraceptives. Ask the pharmacist or contraception service to check the actual method. A general warning to avoid pregnancy is insufficient without a practical, understood prevention and review plan.
Lithium and lamotrigine need ongoing monitoring
Lithium may sometimes be continued in pregnancy after specialist assessment. NHS guidance describes possible early-pregnancy cardiac-development risks and emphasizes reviewing treatment rather than stopping independently. The balance depends on the person’s illness and previous response, not simply the name of the medicine. [4]
Monitoring requirements can change during pregnancy and after birth. Lamotrigine levels can vary substantially across these stages, and NICE recommends appropriate level monitoring. A regimen that was suitable before conception may therefore need review even when symptoms remain stable. Ask which team will order tests, interpret results and communicate any changes. [1]
Antidepressants and continuing effective care
Antidepressants should be considered individually. NHS information states that sertraline can be used during pregnancy when needed, with a discussion of benefits and risks and appropriate care around birth. This is not a recommendation for everyone to switch to sertraline or a guarantee that every SSRI has identical evidence. [5]
A review should ask how severe the previous illness was, whether the medicine has helped and what happened during earlier interruptions. Psychological care can be valuable alongside medication, but it should not be presented as an automatic replacement for treatment that is maintaining stability after serious illness. The patient should participate in the decision and receive clear follow-up.
Antipsychotics, physical health and maternity care
For people taking antipsychotic medication, the maternity team should know the specific treatment and why it is needed. Weight and glucose monitoring may be particularly relevant, and other physical-health conditions can influence the plan. A long-acting injection and an oral product should not be treated as identical practical choices. [1]
Ask how psychiatric and obstetric reviews will be coordinated. If treatment changes, clarify who remains responsible for prescriptions and monitoring. The plan should also address sleep, nutrition, appointments and practical support rather than treating the pregnancy discussion as a single medication decision made once and never revisited.
Breastfeeding is a separate assessment
A medicine’s suitability in pregnancy does not automatically settle its suitability during breastfeeding. The infant’s gestational age, health, feeding and other exposures matter. NHS Specialist Pharmacy Service identifies sertraline and paroxetine as preferred SSRIs in breastfeeding for healthy, full-term infants, but does not advise automatically changing an effective pregnancy SSRI solely to reach a preferred option. [6]
Premature or unwell infants and complex combinations need specialist advice. Discuss signs such as poor feeding or unusual sleepiness with the relevant clinician. Lithium during breastfeeding requires particularly careful specialist assessment and may involve additional testing. Do not interpret a general compatibility list as a substitute for review of the actual parent and infant.
Plan for the period after birth
Prepare the postnatal plan before delivery where possible. It should cover medication review, sleep protection, feeding support, appointments and early signs of deterioration. Ask who to contact if the usual clinician is unavailable. A partner or trusted person may help recognize changes, but involvement should respect the patient’s preferences and privacy.
Postpartum psychosis is a medical emergency, not ordinary baby blues. New hallucinations, delusions, severe confusion or rapidly escalating mania after birth require urgent assessment. Immediate danger to the parent or baby requires emergency help. Do not wait for a routine check or try to manage a severe change by adjusting medicines at home. [7]
Substance use and withdrawal concerns
Discuss alcohol, opioids, nicotine and other substances without waiting to have a complete solution. They can affect mental health, pregnancy care and medication safety. An accurate account allows the team to coordinate appropriate treatment. Concealing use because of shame can make the prescribing picture less safe and should not be necessary to obtain respectful care.
Do not attempt an unsupervised alcohol, opioid or sedative detox during pregnancy. Contact appropriate medical and maternity services for assessment. Withdrawal management, ongoing addiction treatment and psychiatric medication decisions should be coordinated. A prescription for depression or anxiety is not a substitute for that specialist planning.
Questions that make the appointment useful
Ask why each medicine remains necessary, what alternatives have been considered and what would change the recommendation. Clarify contraception, relevant tests, pregnancy-specific precautions, feeding plans and who will review treatment after birth. Request the plan in writing so that maternity, primary-care and mental-health teams have the same information.
Discuss practical barriers such as transport, childcare, language, work and access to prescriptions. A plan is only useful when it can be followed. It should include a route for ordinary questions and a separate route for urgent concerns, with explicit responsibility for any proposed medication change.
Frequently asked questions
Should all psychiatric medicines be stopped before pregnancy?
No. Decisions must consider the specific medicine and the risks of untreated or recurrent illness. Some medicines require urgent changes under specialist supervision; others may appropriately continue.
Does an accidental exposure mean the baby has been harmed?
No such conclusion can be made from the medicine name alone. Obtain prompt advice about the actual exposure, appropriate monitoring and the options available.
Can breastfeeding advice be copied from another person’s prescription?
No. The medicine, dose, combination and infant’s health all matter. A professional review should explain both the treatment and the infant-monitoring plan.
Evidence and sources
- [1] NICE CG192: Antenatal and postnatal mental health.
- [2] MHRA: Valproate reproductive risks.
- [3] MHRA: Topiramate Pregnancy Prevention Program.
- [4] NHS: Lithium in pregnancy and breastfeeding.
- [5] NHS: Sertraline.
- [6] NHS Specialist Pharmacy Service: SSRIs during breastfeeding.
- [7] NHS: Postpartum psychosis.
